173 related articles for article (PubMed ID: 19670450)
1. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Abdeen A; Chou AJ; Healey JH; Khanna C; Osborne TS; Hewitt SM; Kim M; Wang D; Moody K; Gorlick R
Cancer; 2009 Nov; 115(22):5243-50. PubMed ID: 19670450
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis.
Cates JM; Friedman DB; Seeley EH; Dupont WD; Schwartz HS; Holt GE; Caprioli RM; Young PP
Int J Exp Pathol; 2010 Aug; 91(4):335-49. PubMed ID: 20353421
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
4. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.
Sulzbacher I; Birner P; Trieb K; Lang S; Chott A
Virchows Arch; 2002 Oct; 441(4):345-9. PubMed ID: 12404059
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
[TBL] [Abstract][Full Text] [Related]
8. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Lin F; Zheng SE; Shen Z; Tang LN; Chen P; Sun YJ; Zhao H; Yao Y
Med Oncol; 2011 Jun; 28(2):649-53. PubMed ID: 20349215
[TBL] [Abstract][Full Text] [Related]
9. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-337-5p participates in the development and progression of osteosarcoma via ERBB, MAPK and VEGF pathways.
Tian ZG; Zhuang Y; Jin Z; Zhou F; Zhu LF; Shen PC
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5460-5470. PubMed ID: 30229817
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase pathway in osteosarcoma.
Na KY; Kim YW; Park YK
Pathology; 2012 Oct; 44(6):540-6. PubMed ID: 22935974
[TBL] [Abstract][Full Text] [Related]
12. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome.
Mora J; Rodríguez E; de Torres C; Cardesa T; Ríos J; Hernández T; Cardesa A; de Alava E
Pediatr Blood Cancer; 2012 Apr; 58(4):532-8. PubMed ID: 21994054
[TBL] [Abstract][Full Text] [Related]
13. Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma.
Wu H; Zhang J; Dai R; Xu J; Feng H
J Orthop Surg Res; 2019 Sep; 14(1):296. PubMed ID: 31484533
[TBL] [Abstract][Full Text] [Related]
14. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study.
Rastogi S; Kumar R; Sankineani SR; Marimuthu K; Rijal L; Prakash S; Jalan D; Khan SA; Sharma MC
Int Orthop; 2012 Nov; 36(11):2315-21. PubMed ID: 23015149
[TBL] [Abstract][Full Text] [Related]
15. Expression of therapeutic targets in Ewing sarcoma family tumors.
Ahmed AA; Sherman AK; Pawel BR
Hum Pathol; 2012 Jul; 43(7):1077-83. PubMed ID: 22196127
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients.
van de Luijtgaarden AC; Versleijen-Jonkers YM; Roeffen MH; Schreuder HW; Flucke UE; van der Graaf WT
Target Oncol; 2013 Dec; 8(4):253-60. PubMed ID: 23292309
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
18. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.
Zhang C; Wang L; Xiong C; Zhao R; Liang H; Luo X
J Orthop Surg Res; 2021 Dec; 16(1):738. PubMed ID: 34963495
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma.
Rakesh Kumar V; Gupta N; Kakkar N; Sharma SC
J Cancer Res Ther; 2006; 2(1):20-3. PubMed ID: 17998668
[TBL] [Abstract][Full Text] [Related]
20. Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma.
Han I; Lee MR; Nam KW; Oh JH; Moon KC; Kim HS
Clin Orthop Relat Res; 2008 Sep; 466(9):2107-13. PubMed ID: 18563508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
